The triple new drug for chronic obstructive pulmonary disease is Flutimavir Inhalation Powder Mist. Flutimavir Inhalation Powder Mist is a compound preparation with the ingredients of triple new drug including umeclidinium bromide, vilanterol triphosphate and fluticasone propionate, which has the effects of anti-inflammation and bronchodilatation. It can be used for maintenance therapy in the treatment of COPD, but cannot be used as an emergency drug during acute exacerbations. Adverse reactions such as headache, upper respiratory tract infection, nasopharyngitis may occur after the use of Flutemavir Inhalation Powder Mist. In addition, it is prohibited for people who are allergic, heavily allergic to milk proteins, etc., while the product should be used with caution by pregnant women, breastfeeding women and other people. When using medication for treatment, be sure to consult a physician to guide the use of medication, follow the doctor’s instructions, and apply the medication reasonably, do not unauthorized use of medication, so as to avoid the occurrence of adverse reactions.